Compare GSK plc (GSK) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Under Armour Inc Class A — how do they compare? GSK plc trades at $51.53 (market cap $101.34B), while Under Armour Inc Class A trades at $6.85 (market cap $2.89B). The key difference: GSK plc is far larger — about 35.1× Under Armour Inc Class A's market cap, and GSK plc pays a 3.49% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| GSK | UAA | |
|---|---|---|
Market Cap | $101.34B | $2.89B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $8.14 |
52-Week Low | $36.20 | $4.17 |
Enterprise Value | $121.95B | $4.52B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
Under Armour (UAA) trades at $6.61, down 2.07% on the day, with a mixed technical picture showing bullish moving averages but neutral oscillators. Fundamentally, the company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion, though recent quarters have shown some earnings beats. The stock is trading above the consensus price target of $5.96, with analyst sentiment leaning toward Hold.
The outlook remains challenging due to weak North American sales and margin pressure, but international growth and a new Dodge collaboration offer potential catalysts. Key risks include persistent revenue declines, high debt levels, and competitive pressures. Investors should weigh the company's brand strength against ongoing operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
